EPHB2 and colorectal carcinoma: In line with previously published data reporting an intestinal stem cell-specific gene signature linked to LGR5 and EPHB2 expression related to CRC relapse [8], high expression of our stem signature defined by 200 genes (Table S1) in the TCGA cohort displayed decreased progression-free survival (p = 0.068) compared to patients with low expression (Figure 2e).